<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885764</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU P01b / 2021</org_study_id>
    <nct_id>NCT04885764</nct_id>
  </id_info>
  <brief_title>Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University</brief_title>
  <acronym>ASU-VAC</acronym>
  <official_title>Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective intervention study to assess the effectiveness of both the live&#xD;
      attenuated and messenger RNA vaccines against SARS-CoV-2 infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective intervention study to assess the short-term effectiveness of the first&#xD;
      dose of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection by&#xD;
      monitoring the antibodies (IgG, IgM and level of neutralizing antibodies) in sera of&#xD;
      post-vaccinated persons.&#xD;
&#xD;
      The study also will monitor the incidence of SARS-CoV-2 infection among vaccinees just before&#xD;
      the first dose administration, 3 weeks after immunization, at the administration of the&#xD;
      second dose, 14 days following the second dose and after 3 and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term effectiveness</measure>
    <time_frame>21 days of the first dose of vaccine</time_frame>
    <description>Assess the short-term effectiveness of the first dose of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection by monitoring the antibodies (IgG, IgM and level of neutralizing antibodies) in sera of postvaccinated persons three weeks after first dose</description>
  </primary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Covid19</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Astrazeneca/Oxford Vaccine</intervention_name>
    <description>Viral non replicated vector vaccine contains the gene that encodes for the spike protein on the surface of the SARS-CoV-2 virus given Intramuscular injection in 2 doses 3 months apart</description>
    <other_name>Vaxzevria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sinopharm vaccine</intervention_name>
    <description>Inactivated vaccine given intramuscular injection in 2 doses 3 weeks apart</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years old&#xD;
&#xD;
          2. Candidate for receiving vaccination according to health care authorties prioritaizaton&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. SARS-CoV-2 recovered cases &lt;3 months&#xD;
&#xD;
          2. Individuals who are currently infected with Sars-COV-2 and/or with respiratory&#xD;
             symptoms with fever.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samia E Girgis, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samia Girgis, MD</last_name>
    <phone>01223366500</phone>
    <email>drsamia.girgis@med.asu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatma Soliman E Ebeid, MD</last_name>
    <phone>01095569596</phone>
    <email>dr.fatma_ebeid@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center</name>
      <address>
        <city>Cairo</city>
        <state>Non-US</state>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatma Soliman E Ebeid</last_name>
      <phone>01095569596</phone>
      <email>dr.fatma_ebeid@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 8, 2021</study_first_submitted>
  <study_first_submitted_qc>May 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 8, 2021</last_update_submitted>
  <last_update_submitted_qc>May 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Samia Girgis</investigator_full_name>
    <investigator_title>Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt</investigator_title>
  </responsible_party>
  <keyword>Egypt</keyword>
  <keyword>Ain Shams University</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

